We conducted a systematic review of clinical trials registered on ClinicalTrials.gov between October 2019 and October 2024, focusing on pharmacological interventions for obesity from early exploratory stages to Phase 3
NICE to reconsider Alzheimers treatment The National Institute of Clinical Excellence (NICE) will reconsider whether Alzheimers treatment donanemab could be made available on the NHS, following a successful appeal from manufacturer Eli Lilly
These prospective studies will provide definitive evidence about whether these medications can prevent or slow cognitive decline in high-risk populations
Across the full GLP-1 and obesity drug space, the post-2026 picture is a price-expansion wave led by Indian and Chinese biosimilars and by new dual or triple-agonist molecules, yet real uptake in the USA and EU will be shaped less by tariffs and more by regulatory timing, drug-device parity on pens and human-factors equivalence for AB-substitution, secondary IP and Orange Book hurdles, and payer or formulary contracting
What changed
Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus
